Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant influenza hemagglutinin + Advax1
- Development stage
- Unknown
- Lead developer
- Vaxine
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
This is a **combination vaccine formulation** consisting of recombinant influenza hemagglutinin (HA)—the main surface glycoprotein antigen from the influenza virus, produced using recombinant DNA technology—and **Advax1**, a proprietary adjuvant based on delta inulin microparticles. The recombinant HA component elicits strain-specific anti-influenza antibody responses, while Advax1 functions as an *immunomodulatory adjuvant* that enhances the immune response to the protein antigen with a minimal inflammatory profile. Advax1 (delta inulin) is known to enhance both humoral and cellular immunity and has demonstrated safety and tolerability in human clinical trials for various viral vaccines, including influenza. This combination is primarily investigated as a **prophylactic influenza vaccine** candidate, designed to improve immunogenicity and potentially broaden immune responses beyond that of traditional influenza vaccines.
- Other names
- recombinant influenza HA + Advax1recombinant influenza hemagglutinin + Advax-1
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on recombinant influenza hemagglutinin + Advax1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant influenza hemagglutinin + Advax1.